🇮🇳India

अनुदान बजट ओवररन

2 verified sources

Definition

Grant recipients face cost sharing mandates (e.g., 50% for national labs on projects >₹80 lakh) and strict budget heads (equipment, manpower). Manual processes cause undetected overruns, especially with revised estimates showing cuts (e.g., DST R&D from ₹592 crore to ₹200 crore).[2][4]

Key Findings

  • Financial Impact: ₹10-20 लाख per project overrun; 50% cost sharing on >₹80 lakh projects
  • Frequency: Per grant cycle (18-36 months)
  • Root Cause: Manual budget tracking without real-time visibility into scheme-specific allocations

Why This Matters

The Pitch: Biotechnology Research players in India waste ₹10-20 लाख per project on budget overruns. Automation of Grant Budget Tracking eliminates this risk.

Affected Stakeholders

Project PI, Finance Officer, Grant Administrator

Deep Analysis (Premium)

Financial Impact

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Current Workarounds

Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.

Unlock to reveal

Get Solutions for This Problem

Full report with actionable solutions

$99$39
  • Solutions for this specific pain
  • Solutions for all 15 industry pains
  • Where to find first clients
  • Pricing & launch costs
Get Solutions Report

Methodology & Sources

Data collected via OSINT from regulatory filings, industry audits, and verified case studies.

Evidence Sources:

Related Business Risks

अनुदान रिपोर्टिंग अनुपालन दंड

₹5-15 लाख fund withholding per delayed report; typical 10-20% grant clawback

अनुदान ट्रैकिंग क्षमता हानि

20-40 hours/month per project (₹5,000-10,000/hour researcher cost)

प्रोटोकॉल विकास में अतिरिक्त ओवरटाइम लागत

40-80 hours overtime per protocol at ₹2,000/hour = ₹80,000-1.6 लाख + consultant fees ₹10-20 लाख[1][3]

EC स्वीकृति रुकावट से क्षमता हानि

30-90 days idle site capacity at ₹1-2 लाख/day = ₹30-180 लाख per trial[1]

अनुमोदन योजना की दृश्यमानता में कमी (Poor Regulatory Approval Visibility)

Estimated ₹1–2 crore annual opportunity cost per biotech firm due to misdirected R&D spending on stalled products and delayed portfolio shifts; 10–15% capital misallocation estimated across Indian biotech sector (₹50–100 crore aggregate annually for sector).

Request Deep Analysis

🇮🇳 Be first to access this market's intelligence